Medicines Co. (MDCO) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
February 27, 2019 7:00 AM ESTContinued progress in inclisirans development, with no material safety issues to date, paves the way for topline pivotal trial readouts expected in 3Q Inclisirans unique profile, vast global market opportunity and long-dated exclusivity set the stage for significant shareholder value creation
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2018.
During 2018 we successfully restructured our business and executed on our development plan for inclisiran, a... More
